SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Potential Offer

6 Sep 2010 15:14

RNS Number : 2239S
Silence Therapeutics PLC
06 September 2010
 



 

 

FOR IMMEDIATE RELEASE

 

Potential Offer

 

London, 6 September, 2010 - Silence Therapeutics plc (AIM: SLN) notes the recent share price movement and announces that it has received an approach which may or may not lead to an offer for the Company. A further announcement will be made in due course.

 

For further information, please contact:

 

Silence Therapeutics

Phil Haworth, CEO +1 (650) 855-1514

p.haworth@silence-therapeutics.com

NOMAD

Nomura Code Securities

Richard Potts / Jonathan Senior

+44 20 7776 1200

 

European media and investor enquiries:

M:Communications +44 20 7920 2342

Mary-Jane Elliott / Emma Thompson

 

US media and investor enquiries:

Vida Communication +44 (415) 675-7400

Tim Brons (media)

tbrons@vidacommunication.com 

or

Stephanie Diaz (investors)

sdiaz@vidacommunication.com

 

The City Code on Takeovers and Mergers (the "City Code")

 

1) Rule 2.10 of the City Code

 

In accordance with Rule 2.10 of the City Code, the Company confirms that it has 279,891,452 ordinary shares of 1p each in issue under the ISIN code GB0008433350.

 

2) Disclosure requirements of the Takeover Code (the "Code")

 

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SPMZQLFBBKFBBBK
Date   Source Headline
11th Jul 20187:00 amRNSLicensee Quark Pharmaceuticals Patient Dosed Ph 3
21st Jun 20187:00 amRNSSilence Strengthens Board and Leadership Team
18th Jun 20184:35 pmRNSPrice Monitoring Extension
15th Jun 20187:00 amRNSPresents Data on Lead Programme SLN124 at EHA
4th Jun 201810:15 amRNSSilence Therapeutics Announces Leadership Change
24th Apr 20187:00 amRNSResults of AGM
19th Apr 20185:00 pmRNSAdditional Listing
3rd Apr 20187:00 amRNSLitigation Update (Portugal and US)
26th Mar 20187:00 amRNSSilence to Present at Scientific Conferences
7th Mar 20187:00 amRNSNotice of AGM
6th Mar 20187:00 amRNSPreliminary results year ended 31 December 2017
5th Mar 20187:00 amRNSSilence to present at Cowen Health Care Conference
22nd Feb 20183:40 pmRNSHolding(s) in Company
20th Feb 20187:00 amRNSNotice of Results
15th Feb 20182:27 pmRNSAdditional Listing
2nd Feb 201811:38 amRNSGrant of share options and restricted stock units
2nd Feb 20188:58 amRNSHolding(s) in Company
31st Jan 201811:48 amRNSHolding(s) in Company
22nd Jan 20187:00 amRNSKey European patent granted
8th Jan 20187:00 amRNSPost year end business update
28th Dec 20177:00 amRNSFurther Partial Disposal - Arrowhead common shares
15th Dec 20174:40 pmRNSSecond Price Monitoring Extn
15th Dec 20174:35 pmRNSPrice Monitoring Extension
14th Dec 20174:35 pmRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSFurther Partial Disposal - Arrowhead common shares
4th Dec 20177:00 amRNSPartial Disposal of Arrowhead common shares
20th Nov 20177:00 amRNSUpdate on litigation matters
14th Nov 20177:00 amRNSCapital Markets Day
3rd Nov 20177:00 amRNSUpdate on Litigation Matters
2nd Nov 20174:40 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20179:24 amRNSHolding(s) in Company
24th Oct 20173:59 pmRNSHolding(s) in Company
19th Oct 20175:50 pmRNSHolding(s) in Company
18th Oct 20172:31 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSFurther US patents granted
17th Oct 20173:08 pmRNSServing of claim in the UK High Court
16th Oct 20177:00 amRNSAppointment of Non-Executive Chair
11th Oct 20177:00 amRNSKey US patent granted
6th Oct 20172:40 pmRNSHolding(s) in Company
28th Sep 20171:10 pmRNSHolding(s) in Company
27th Sep 20172:39 pmRNSHolding(s) in Company
27th Sep 20179:48 amRNSHolding(s) in Company
26th Sep 201711:48 amRNSHolding(s) in Company
22nd Sep 20174:00 pmRNSHolding in Company
22nd Sep 20173:15 pmRNSHolding in Company
22nd Sep 20172:15 pmRNSHolding in Company
22nd Sep 20172:01 pmRNSHolding in Company
22nd Sep 20172:00 pmRNSHolding in Company
20th Sep 201712:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.